December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Prevention of Secondary Cataracts by Targeting Proliferating Lens Epithelial Cells by Somatic Gene Therapy
Author Affiliations & Notes
  • F Nessi
    Unity of Ophthalmic Genetics Jules Gonin Eye Hospital University of Lausanne Lausanne Switzerland
  • P Lachat
    Institute of Microbiology and Institute of Pathology CHUV University of Lausanne Lausanne Switzerland
  • R Sahli
    Institute of Microbiology and Institute of Pathology CHUV University of Lausanne Lausanne Switzerland
  • M Sickenberg
    Unity of Ophthalmic Genetics Jules Gonin Eye Hospital University of Lausanne Lausanne Switzerland
  • PH Shaw
    Institute of Microbiology and Institute of Pathology CHUV University of Lausanne Lausanne Switzerland
  • F Munier
    Unity of Ophthalmic Genetics Jules Gonin Eye Hospital University of Lausanne Lausanne Switzerland
  • Footnotes
    Commercial Relationships   F. Nessi, None; P. Lachat, None; R. Sahli, None; M. Sickenberg, None; P.H. Shaw, None; F. Munier, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2354. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F Nessi, P Lachat, R Sahli, M Sickenberg, PH Shaw, F Munier; Prevention of Secondary Cataracts by Targeting Proliferating Lens Epithelial Cells by Somatic Gene Therapy . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2354.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Posterior capsule opacification (PCO) is a common complication that affects 30-50% of patients within two years after cataract surgery. The proliferation of residual lens epithelial cells (LECs) after surgery is responsible for PCO. It most frequently occurs following surgery in children with congenital cataracts. Actually PCO may be treated with YAG-capsulotomy. However this treatment is expensive and presents some contre-indications in terms of costs, ocular complications, feasibility and efficacy. The authors describe preliminary results of a patented procedure based on somatic gene therapy, which is intended to prevent cell growth on the posterior capsule. Methods: Lens capsules were isolated from pig eyes, sterile PMMA capsular tension rings inserted and the preparations placed in culture medium. Pig lens capsules were then infected by a non-replicative recombinant adenovirus expressing the thymidine kinase from HSV1 (Ad-HSV1TK) or the green fluorescent protein (GFP) in a cell-specific manner. LEC-specific expression of the foreign genes delivered by the recombinant adenoviruses is achieved with one of three promoters: a Major Intrinsic Protein gene promoter (Ad-MIP-HSV1TK), a ßA3/A1-crystallin gene promoter (Ad-ßA3/A1-cry-HSV1TK), a αB-crystallin promoter (Ad-αB-cry-HSV1TK). LECs infected by Ad-HSV1TK undergo cell death in the presence of the prodrug ganciclovir (GCV). Lens capsules are cultured for 4 weeks and examined every 5 days for LECs proliferation state. Results: Sixty pig lens capsules were isolated. Twenty were used to assess the conditions of organo-culture and infections by the recombinant adenoviruses. We only observed GFP expression in LECs infected by adenoviruses expressing GFP under the control of αB-crystallin, ßA3/A1-crystallin or Major Intrinsic Protein promoter. No PCO of lens capsule cultures by LECs were observed for a viral dose of 7.105 and 5.106 pfu Ad-αBcry-HSV1TK in the presence of GCV compared to the lens capsules controls covered by LECs in 10 days. Conclusion: Although further studies will be necessary, the delivery of a suicide gene specifically expressed in LECs by recombinant adenovirus may be considered as a preventive measure for PCO when used at time of primary cataract surgery.

Keywords: 419 gene transfer/gene therapy • 522 posterior capsular opacification (PCO) • 338 cataract 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×